eligibility_summary
Adults ≥18 with advanced solid tumors after standard therapy failure/intolerance, RECIST 1.1 measurable lesion (non‑brain/bone), tumor tissue, ECOG 0–1, >12‑wk survival, contraception, consent. Excludes prior Trop‑2 ADCs, recent systemic therapy/radiation/surgery, interacting or QT‑prolonging drugs, unresolved ≥G2 toxicity, uncontrolled CNS disease/effusions, inadequate marrow/organ function or uncontrolled comorbidities, bleeding/thrombosis/infection, moderate‑severe liver disease, pregnant or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: HS-20105, an intravenous antibody–drug conjugate (ADC) dosed every 21 days. Mechanism of action: a monoclonal antibody binds Trop-2 (TACSTD2) on tumor cell surfaces, is internalized, and releases an attached cytotoxic payload inside the cell to induce cancer cell death. Trial goal: first-in-human Phase I dose escalation/expansion to define MTD/DLT, assess PK, safety, and preliminary antitumor activity in advanced solid tumors. Targets: Trop-2–expressing epithelial tumor cells, utilizes Trop-2–mediated endocytosis/trafficking to deliver intracellular chemotherapy.